DHEA-S: The Adrenal Marker That Declines With Age
It declines more predictably with age than almost any hormone, which makes it an appealing ageing marker and a poor intervention target.
The Short Answer
Dehydroepiandrosterone sulphate is the most abundant circulating steroid, produced largely by the adrenal cortex, and it declines steadily from the third decade to a fraction of peak by later life. That decline is so consistent that DHEA-S is sometimes proposed as an ageing marker. Whether restoring it does anything is a separate question, and the supplementation trials have been largely unimpressive despite the appealing logic.
What It Is and Why It Declines
DHEA is synthesised in the adrenal zona reticularis and circulates predominantly as its sulphate ester, DHEA-S, which has a longer half-life and higher concentration. It functions as a precursor: peripheral tissues convert it to androgens and oestrogens according to local enzyme expression, which is why its effects differ between tissues and between sexes.
Production peaks in the twenties and declines progressively, a phenomenon termed adrenopause. The decline is specific to the zona reticularis, since cortisol production from the zona fasciculata is largely maintained, which means the ratio of DHEA-S to cortisol falls with age.
The decline is steadier and less variable than most hormonal changes, which is what makes it attractive as a marker. It is also affected by acute illness, chronic stress, glucocorticoid use and adrenal disease, which limits its specificity.
Interpretation requires age and sex-specific reference ranges, since a value normal for a 60-year-old would be markedly low for a 25-year-old. Laboratories vary in whether they report age-adjusted ranges, and reading a result against an all-adult range is a common error.
The Associations and the Trials
Observational. Lower DHEA-S associates with cardiovascular events, mortality, reduced bone density, depression, frailty and cognitive decline in various cohorts. The associations are real and their interpretation is complicated by the fact that DHEA-S falls with illness of almost any kind, which makes reverse causation plausible.
Supplementation trials. The picture is largely negative for healthy older adults. Trials of DHEA supplementation have generally shown small or no effects on body composition, physical function, cognition, mood and quality of life, with some reporting modest bone density effects in women and some improvement in skin measures.
Where it does have an established role: adrenal insufficiency, where DHEA replacement has been studied and shows some benefit for wellbeing and libido in women; and specific clinical contexts including intravaginal DHEA for genitourinary symptoms of menopause, which is a licensed use in some jurisdictions.
The interpretation that fits. DHEA-S is plausibly a marker of adrenal and general health status rather than a driver of it, which would explain both the consistent associations and the disappointing supplementation results. That pattern recurs across ageing biomarkers.
Supplementation, and Why It Is Not a Supplement
| Issue | Detail |
|---|---|
| Regulatory status | Available over the counter in some jurisdictions, prescription-only in others including much of Europe |
| Conversion unpredictability | Converts to androgens and oestrogens according to local tissue enzymes; the resulting profile is not controllable |
| Androgenic effects in women | Acne, hirsutism, voice change, scalp hair loss reported |
| Oestrogenic effects | Relevant to anyone with hormone-sensitive conditions |
| Suppression concern | Exogenous precursor may suppress endogenous production |
| Product quality | Independent testing has found substantial content variation |
| Doping status | Prohibited in sport |
| Panel confusion | Raises androgen and oestrogen measurements, complicating subsequent hormone interpretation |
The unpredictable conversion is the central objection. Taking a precursor whose downstream products depend on tissue enzyme expression means accepting an uncontrolled hormonal exposure, which is a different proposition from taking a defined hormone at a defined dose under monitoring.
Anyone with a personal or family history of hormone-sensitive cancer, PCOS, or any hormonal condition has a specific reason to avoid it, and anyone considering it at all has a reason to do so with clinical oversight rather than self-directed.
What Actually Supports Adrenal Androgen Status
Since DHEA-S declines with illness, stress and glucocorticoid exposure, the modifiable contributors are general rather than specific.
Adequate energy availability. Sustained deficit suppresses adrenal androgen production alongside gonadal function.
Sleep. Chronic restriction affects the hypothalamic-pituitary-adrenal axis.
Chronic stress management. Sustained cortisol elevation is associated with a lower DHEA-S to cortisol ratio.
Avoiding unnecessary glucocorticoid exposure, where clinically possible, since exogenous glucocorticoids suppress adrenal production.
Addressing the underlying illness, where one is present, since DHEA-S falls with almost any significant illness.
What does not have evidence: adaptogens raising DHEA-S meaningfully, adrenal glandular supplements, or protocols marketed for adrenal fatigue, which is not a recognised condition and whose salivary testing panels are not validated.
The honest summary is that DHEA-S is more useful as a reflection of overall status than as a target, and the interventions that improve overall status are the familiar ones.
When to Measure It
Clinically indicated: investigating androgen excess in women, where DHEA-S helps distinguish adrenal from ovarian sources and markedly elevated values raise the question of an adrenal tumour; investigating adrenal insufficiency alongside other tests; and assessing children with early or delayed puberty.
Reasonable in a longevity panel: as one input among several, read against age and sex-specific ranges, with the understanding that a low value in an unwell person reflects the illness.
Not useful: as a stand-alone ageing measure to act on, as a target for supplementation in healthy adults, or as part of an adrenal fatigue assessment.
Interpretive notes: measure in the morning for consistency, though DHEA-S varies less across the day than cortisol; note any glucocorticoid use, including inhaled and topical, which suppresses it; and note that oral contraceptives and pregnancy shift adrenal androgen measurements.
Markedly elevated DHEA-S in either sex warrants clinical assessment, since it can indicate an adrenal tumour or congenital adrenal hyperplasia.
The Pattern Worth Recognising
DHEA-S is a good example of a category worth recognising across this cluster: hormones that decline reliably with age, associate with adverse outcomes when low, and disappoint when supplemented.
Growth hormone and IGF-1 show a similar pattern, with the added complication that lower IGF-1 associates with longevity in several models. Testosterone declines with age and responds to replacement in genuine symptomatic deficits while showing limited benefit as an anti-ageing intervention in men with normal levels. Melatonin declines and has a narrow, timing-specific use.
The common structure: the decline is real, the association is real, and the inference that restoration will help skips a step. Declines may be adaptive, protective, or simply downstream of the ageing process rather than causing it.
That does not mean hormone replacement is never appropriate. It means the argument from "this declines with age" to "therefore restore it" requires trial evidence, and where the trials have been run, the results have more often been disappointing than confirmatory.
The AEONNN Perspective
AEONNN reads DHEA-S as a status reflection rather than a target, and the Evidence layer explains why: the observational associations are consistent while supplementation trials in healthy older adults have been largely negative. The likeliest interpretation is that it falls with illness and general decline rather than driving them, which recurs across ageing biomarkers.
The Regulatory and Safety layers put it outside what the platform recommends for self-directed use. It is prescription-only in many jurisdictions, it converts unpredictably to androgens and oestrogens according to local tissue enzymes, and it raises subsequent hormone measurements in ways that complicate interpretation. Anyone with a hormone-sensitive condition has a specific reason to avoid it.
It maps to Pillar 2 and Pillar 10, and the platform reads it against age and sex-specific ranges, since a value normal at 60 is markedly low at 25. The broader pattern it illustrates is one AEONNN applies generally: a hormone declining with age does not license restoring it, and where those trials have run, the results have more often disappointed than confirmed.
Pillar Matrix mapping
Hormonal Optimization and Vitality, Longevity and Biological Age
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Safety Layer (DrugBank, FAERS)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
What is DHEA-S?
The sulphate ester of dehydroepiandrosterone, the most abundant circulating steroid, produced by the adrenal cortex and functioning as a precursor that peripheral tissues convert to androgens and oestrogens.
Why does DHEA-S decline with age?
Production in the adrenal zona reticularis declines progressively from the third decade, a phenomenon termed adrenopause, while cortisol production is largely maintained.
Does DHEA supplementation work?
Trials in healthy older adults have generally shown small or no effects on body composition, function, cognition and mood, with some modest bone and skin findings. It has established roles in adrenal insufficiency and in specific clinical uses.
Is DHEA safe to take?
It converts unpredictably to androgens and oestrogens according to tissue enzymes, causes androgenic effects in women, is prescription-only in many jurisdictions and is prohibited in sport. It warrants clinical oversight.
What raises DHEA-S naturally?
Nothing specific with good evidence. Adequate energy availability, sleep, stress management and avoiding unnecessary glucocorticoid exposure support adrenal function generally.
Is DHEA-S useful for adrenal fatigue?
Adrenal fatigue is not a recognised condition and its salivary testing panels are not validated. DHEA-S has genuine clinical uses in androgen excess and adrenal insufficiency assessment.
When should DHEA-S be measured?
When investigating androgen excess in women, assessing adrenal insufficiency, or as one input in a broader panel read against age and sex-specific ranges. Markedly elevated values warrant clinical assessment.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.